2012, ISBN: 9783642282959
Springer, Gebundene Ausgabe, Auflage: 2012, 244 Seiten, Publiziert: 2012-03-22T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 8 black & white tables, biography, 1.18 kg, Rechtsmedizin, M… Altro …
amazon.de The Cotswold Library Gebraucht, wie neu. Costi di spedizione:Auf Lager. Die angegebenen Versandkosten können von den tatsächlichen Kosten abweichen. (EUR 3.00) Details... |
2012, ISBN: 9783642282959
Springer, Gebundene Ausgabe, Auflage: 2012, 244 Seiten, Publiziert: 2012-03-22T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 8 black & white tables, biography, 1.18 kg, Rechtsmedizin, M… Altro …
amazon.de Costi di spedizione:Die angegebenen Versandkosten können von den tatsächlichen Kosten abweichen. (EUR 3.00) Details... |
2012, ISBN: 3642282954
2012 Gebundene Ausgabe Krebs (Krankheit), Tumor / Krebs, MitogenActivatedProteinKinase(MAPK); Rafkinases; Biomarkers; chemicallibrary; clinicaltrialdesign; drugdevelopment; drugefficacy… Altro …
Achtung-Buecher.de MARZIES.de Buch- und Medienhandel, 14621 Schönwalde-Glien Costi di spedizione:Versandkostenfrei innerhalb der BRD. (EUR 0.00) Details... |
2012, ISBN: 9783642282959
[PU: Springer Berlin], Buchschnitt verkürzt - gepflegter, sauberer Zustand - 2012 Ausgabejahr 11863221/12, DE, [SC: 0.00], gebraucht; sehr gut, gewerbliches Angebot, 2012, PayPal, Klarna-… Altro …
booklooker.de |
2012, ISBN: 9783642282959
Buch, Hardcover, 2012, [PU: Springer Berlin], Springer Berlin, 2012
lehmanns.de Costi di spedizione:sofort lieferbar. (EUR 0.00) Details... |
Therapeutic Kinase Inhibitors (Current Topics in Microbiology and Immunology, 355, Band 355) - copertina rigida, flessible
2012, ISBN: 9783642282959
Springer, Gebundene Ausgabe, Auflage: 2012, 244 Seiten, Publiziert: 2012-03-22T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 8 black & white tables, biography, 1.18 kg, Rechtsmedizin, M… Altro …
2012, ISBN: 9783642282959
Springer, Gebundene Ausgabe, Auflage: 2012, 244 Seiten, Publiziert: 2012-03-22T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 8 black & white tables, biography, 1.18 kg, Rechtsmedizin, M… Altro …
2012
ISBN: 3642282954
2012 Gebundene Ausgabe Krebs (Krankheit), Tumor / Krebs, MitogenActivatedProteinKinase(MAPK); Rafkinases; Biomarkers; chemicallibrary; clinicaltrialdesign; drugdevelopment; drugefficacy… Altro …
2012, ISBN: 9783642282959
[PU: Springer Berlin], Buchschnitt verkürzt - gepflegter, sauberer Zustand - 2012 Ausgabejahr 11863221/12, DE, [SC: 0.00], gebraucht; sehr gut, gewerbliches Angebot, 2012, PayPal, Klarna-… Altro …
2012, ISBN: 9783642282959
Buch, Hardcover, 2012, [PU: Springer Berlin], Springer Berlin, 2012
Dati bibliografici del miglior libro corrispondente
Informazioni dettagliate del libro - Therapeutic Kinase Inhibitors (Current Topics in Microbiology and Immunology, 355, Band 355)
EAN (ISBN-13): 9783642282959
ISBN (ISBN-10): 3642282954
Copertina rigida
Anno di pubblicazione: 2012
Editore: Mellinghoff, Ingo K. Sawyers, Charles L. Springer
234 Pagine
Peso: 0,492 kg
Lingua: Englisch
Libro nella banca dati dal 2007-02-22T17:09:48+01:00 (Rome)
Pagina di dettaglio ultima modifica in 2023-06-06T14:17:49+02:00 (Rome)
ISBN/EAN: 9783642282959
ISBN - Stili di scrittura alternativi:
3-642-28295-4, 978-3-642-28295-9
Stili di scrittura alternativi e concetti di ricerca simili:
Autore del libro : mell, sawyer, mellin, melling
Titolo del libro: kina kina, ingo, microbiology
Dati dell'editore
Autore: Ingo K. Mellinghoff; Charles L. Sawyers
Titolo: Current Topics in Microbiology and Immunology; Therapeutic Kinase Inhibitors
Editore: Springer; Springer Berlin
234 Pagine
Anno di pubblicazione: 2012-03-22
Berlin; Heidelberg; DE
Stampato / Fatto in
Lingua: Inglese
160,49 € (DE)
164,99 € (AT)
177,00 CHF (CH)
POD
X, 234 p.
BB; Hardcover, Softcover / Medizin/Nichtklinische Fächer; Onkologie; Verstehen; Medizin, Gesundheit; Mitogen Activated Protein Kinase (MAPK); Raf kinases; biomarkers; chemical library; clinical trial design; drug development; drug efficacy; epigenetics; gastrointestinal stromal tumor (GIST); genetically engineered mouse models (GEMMs); glioblastoma; lung adenocarcinoma; lung cancer; melanoma; myeloproliferative neoplasms; small molecules; Cancer Biology; EA; BC
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.
This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.
This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors hope these lessons will be instructive for the novice as well as the expert.
Includes supplementary material: sn.pub/extras
Altri libri che potrebbero essere simili a questo:
Ultimo libro simile:
9783642445804 Therapeutic Kinase Inhibitors (Sawyers, Charles L. (Herausgeber); Mellinghoff, Ingo K. (Herausgeber))
< Per archiviare...